Who are Docetaxel combined + Trastuzumab +Pertuzumab's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/docetaxel-combined-trastuzumab-pertuzumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Docetaxel combined + Trastuzumab +Pertuzumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Docetaxel combined + Trastuzumab +Pertuzumab (Docetaxel combined + Trastuzumab +Pertuzumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy + HER2-targeted monoclonal antibody combination. Area: Oncology.

phase 3 Chemotherapy + HER2-targeted monoclonal antibody combination HER2 (trastuzumab and pertuzumab); microtubule stabilization (docetaxel) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Docetaxel combined + Trastuzumab +Pertuzumab (Docetaxel combined + Trastuzumab +Pertuzumab) — Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. This combination uses a microtubule-stabilizing chemotherapy agent (docetaxel) together with two HER2-targeting monoclonal antibodies (trastuzumab and pertuzumab) to inhibit HER2-driven cancer cell growth through multiple mechanisms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Docetaxel combined + Trastuzumab +Pertuzumab TARGET	Docetaxel combined + Trastuzumab +Pertuzumab	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	phase 3	Chemotherapy + HER2-targeted monoclonal antibody combination	HER2 (trastuzumab and pertuzumab); microtubule stabilization (docetaxel)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy + HER2-targeted monoclonal antibody combination class)

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Docetaxel combined + Trastuzumab +Pertuzumab — Competitive Intelligence Brief. https://druglandscape.com/ci/docetaxel-combined-trastuzumab-pertuzumab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab